Lisata Therapeutics, Inc. (LSTA)
Lisata adds biopharma finance veteran Jeffrey Farrow to board
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) said it has appointed Jeffrey Farrow, a veteran biopharma finance executive, to its board of directors. Farrow fills a newly created seat, expanding the board from seven to eight members.
Lisata Therapeutics wins new US patent for pancreatic cancer drug
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) has been granted a new US patent covering its experimental drug certepetide for the treatment of pancreatic cancer and other solid tumors, the company said. The US Patent and Trademark Office issued the Method of Use patent titled "Methods for Treating Pancreatic Cancer and Other Solid Tumors.
Lisata subsidiary Marea Therapeutics gets late-breaking slot at AHA Scientific Sessions
Marea Therapeutics, a subsidiary of Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE), said data from the Phase 2b TYDAL study of its lead candidate MAR001 will be presented in a late-breaking science session at the American Heart Association Scientific Sessions 2026 in Chicago. MAR001 is an experimental antibody that blocks a protein called ANGPTL4, which helps fat tissue work properly, with the goal of lowering triglycerides and improving how the body handles fat.
Lisata Therapeutics acquires Marea Therapeutics, secures $225 million private placement
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) has acquired Marea Therapeutics, a clinical-stage biotech developing next-generation medicines for cardioendocrine diseases. The companies also entered a private placement financing agreement expected to raise approximately $225 million in gross proceeds.
Anthropic is compounding, OpenAI is flatlining, and the betting markets have noticed
Two of the biggest listings in market history are queued up for the back end of this year, and punters are already pricing the run-in. Polymarket has opened...
Lisata Therapeutics moves forward with legal action following Kuva merger termination
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) said on Tuesday it has taken decisive action following the termination of its merger agreement with Kuva Labs and its subsidiary Kuva Acquisition Corp, filing suit to protect stockholder interests and moving swiftly to strengthen its financial position. The clinical-stage pharmaceutical company, which develops therapies for advanced solid tumors, filed the lawsuit in the Delaware Court of Chancery, alleging Kuva breached the merger agreement dated March 6, 2026.
Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) has agreed to be acquired by privately held Kuva Labs Inc. for $4 per share in cash, plus a contingent value right worth up to an additional $3.00 per share tied to drug development milestones.
Lisata Therapeutics to be acquired by Kuva Labs
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE), a clinical-stage pharmaceutical company developing therapies to treat advanced solid tumors and other serious diseases, announced that it has agreed to be acquired by privately held Kuva Labs. Under the terms of a definitive agreement, Kuva will launch a tender offer to purchase all outstanding Lisata shares for $5 per share in cash at closing, plus one contingent value right (CVR) per share.
Lisata regains China rights to pancreatic cancer drug
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) said it has mutually terminated a licensing and collaboration agreement with China's Qilu Pharmaceutical, regaining full rights to its cancer drug candidate certepetide in the Greater China region. The February 2021 agreement granted Qilu exclusive rights to develop and commercialize certepetide in Mainland China, Hong Kong, Macau and Taiwan.
Lisata Therapeutics to be acquired by Kuva Labs in $4-per-share cash deal
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) said on Wednesday it has agreed to be acquired by privately held Kuva Labs in a cash deal valuing the clinical-stage drug developer at $4 per share, plus potential contingent payments tied to regulatory and licensing milestones. Under the terms of a binding term sheet, Kuva will launch a tender offer to buy all outstanding Lisata shares for $4 each in cash, with shareholders also eligible to receive up to $2 per share through two non-tradeable contingent value rights, Lisata said.
Lisata Therapeutics, Inc. (LSTA) Q3 2025 Earnings Call Transcript
Lisata Therapeutics, Inc. ( LSTA ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants John Menditto - Vice President of Investor Relations & Corporate Communications David Mazzo - President, CEO & Director James Nisco - Senior VP of Finance, Treasurer, CAO & Principal Financial and Accounting Officer Kristen Buck - Executive VP of R&D and Chief Medical Officer Conference Call Participants Lander Egaña-Gorroño Robert Sassoon - Water Tower Research LLC Peter Enderlin - MAZ Capital Advisors, LLC Brian Kemp Dolliver - Brookline Capital Markets, LLC, Research Division Presentation Operator Welcome to the Lisata Therapeutics Third Quarter 2025 Financial Results and Business Update Conference Call. [Operator Instructions] As a reminder, this call is being recorded today, Thursday, November 6, 2025.
Lisata Therapeutics advances certepetide, inks strategic alliances in Q3
Lisata Therapeutics Inc (NASDAQ:LSTA) has reported financial results for the third quarter, highlighting continued clinical progress for its lead investigational therapy, certepetide, and announcing strategic collaborations to expand its development and discovery capabilities. Certepetide, Lisata's proprietary investigational peptide, continues to be studied across multiple solid tumor types in combination with standard anti-cancer therapies.
